BIO Notebook: Sanofi Hunts For Later-Stage Assets; Orphan Drug Sponsors Hunt For Legislative Fixes

Also, Novavax looks to turn its also-ran vaccine into a contender by banking on tolerability as government support recedes and the US COVID market goes commercial.